{"doi":"10.1007/s11060-025-05209-4","title":"Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis","abstract":null,"journal":"Journal of Neuro-Oncology","year":2025,"id":631781,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1624710,"name":"Atsushi Kambe","orcid":"0000-0002-7173-5915","position":1,"is_corresponding":false},{"id":1624711,"name":"Hidefumi Amisaki","orcid":null,"position":2,"is_corresponding":false},{"id":1624712,"name":"Tomohiro Hosoya","orcid":null,"position":3,"is_corresponding":false},{"id":1560899,"name":"Makoto Sakamoto","orcid":"0009-0003-8805-4440","position":4,"is_corresponding":false},{"id":1624713,"name":"Masamichi Kurosaki","orcid":"0009-0000-3695-0479","position":5,"is_corresponding":false},{"id":1624709,"name":"Irfan Kesumayadi","orcid":"0000-0001-7517-0942","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis","abstract":"<h4>Introduction</h4>Hypertension, the most common adverse events associated with bevacizumab (BEV) treatment, has been proposed as a potential biomarker of treatment response in glioblastoma (GBM) patients. This study aimed to evaluate whether the timing of hypertension serves as a prognostic value in GBM patients.<h4>Methods</h4>This retrospective study consisting of 56 GBM patients treated with initial BEV between 2013 and 2024. Blood pressure was monitored peri-infusion of BEV (before and 60 min after). Patients were grouped into normotension, pre-existing hypertension (before first BEV infusion), and BEV-induced hypertension, further classified as early new-onset (≤ 3 cycles) or late-onset (> 3 cycles). Overall survival (OS) was assessed using the Kaplan-Meier method.<h4>Results</h4>Fifteen (36.6%) patients had pre-existing hypertension, while 26 (63.4%) were normotensive at baseline. Among the normotensive patients, twelve (46.1%) developed early new-onset hypertension, and 13 (50%) developed late-onset hypertension. Patients with pre-existing hypertension demonstrated significantly longer median OS compared to normotensive patients (32 vs. 22 months, p = 0.043). Early new-onset hypertension was also associated with improved OS compared to patients who remained normotensive after three cycles (25 vs. 16 months, p = 0.003). Additionally, patients with pre-existing and early new-onset hypertension showed longer OS compared to those with late-onset hypertension (25 vs. 14 months, p = 0.002).<h4>Conclusion</h4>Monitoring blood pressure during peri-infusion of BEV could be useful in predicting treatment response for GBM patients. Pre-existing or early new-onset hypertension is associated with improved survival, suggesting that timing of hypertension has a potential role as a biomarker for BEV efficacy.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40924324","pmcid":null,"openalex_id":"https://openalex.org/W4414081320","authors":[],"funders":[{"funder_name":"Japan Society for the Promotion of Science","grant_id":"JP23K08520","title":null}],"total_grants":1,"fwci":0.0,"citation_percentile":0.28819353,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://www.springernature.com/gp/researchers/text-and-data-mining","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s11060-025-05209-4.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s11060-025-05209-4/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s11060-025-05209-4","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40924324","host_type":"repository"}],"fields_of_study":["Glioma Diagnosis and Treatment","Angiogenesis and VEGF in Cancer","Brain Metastases and Treatment","Medicine"],"mesh_terms":["Bevacizumab","Antineoplastic Agents, Immunological","Adult","Aged","Brain Neoplasms","Female","Follow-Up Studies","Glioblastoma","Humans","Hypertension","Male","Middle Aged","Prognosis","Retrospective Studies","Time Factors"],"keywords":["Glioblastoma","Blood pressure","Value (mathematics)","Retrospective cohort study","Biomarker","Overall survival","Survival analysis","Hypertension","Survival","timing","Bevacizumab"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T00:41:13.949271Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}